Suomi - suomi - Fimea (Suomen lääkevirasto)

nordic drugs ab - aluminium hydroxide gel, calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

nordic drugs ab - alginic acid, aluminium hydroxide gel, dried, sodium hydrogen carbonate - purutabletti - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

ferring ab - liuosta varten haihtua,natrii bicarbonas,happo alginicum - jauhe - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

ferring ab - liuosta varten haihtua,happo alginicum,natrii bicarbonas - annosjauhe - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

paranova oy - liuosta varten-geeli.,natrii hydrogenocarbonas,natrii alginas,kalsiumia carbonas - oraalisuspensio - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium bicarbonate - oraalisuspensio, annospussi - 500 mg / 213 mg / 325 mg - algiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - mirtazapinum - tabletti, kalvopäällysteinen - 15 mg - mirtatsapiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - mirtazapinum - tabletti, kalvopäällysteinen - 30 mg - mirtatsapiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - mirtazapinum - tabletti, kalvopäällysteinen - 45 mg - mirtatsapiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

actavis group ptc ehf - imatinibi - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. vaikutukset imatinibi on luuytimensiirron lopputulokseen ei ole selvitetty. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kokemusta imatinib potilailla, joilla on mds/mpd, jotka liittyvät pdgfr-geenin uudelleenjärjestäytymisen yhteydessä järjestelyt on hyvin rajallinen. ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia.